close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rocket Pharmaceuticals, Inc. - Common Stock (NQ:RCKT)

2.930 +0.090 (+3.17%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rocket Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty ↗
Rocket Pharmaceuticals faces trial delays, multiple downgrades, and reduced success expectations following RP-A501 safety concerns. 
Via Benzinga
News headline image
Booz Allen, FreshPet, Rocket Pharma Downgraded, While Vail Resorts And FICO Get An Upgrade – Top Wall Street Analyst Calls Today ↗
State Street received an upgrade from Truist, raising the stock to ‘Buy’ from ‘Hold’ and increasing its price target to $112 from $85. 
Via Stocktwits
Topics ETFs Stocks
News headline image
Williams Companies To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
These Analysts Slash Their Forecasts On Rocket Pharmaceuticals ↗
 
Via Benzinga
News headline image
This Informatica Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday ↗
 
Via Benzinga
News headline image
Top 3 Health Care Stocks That Could Blast Off This Month ↗
 
Via Benzinga
News headline image
Patient Death In Rocket Pharma Trial Triggers Downgrades, But Retail Traders Bet Big On Strong Recovery ↗
Message volume on Stocktwits spiked to ‘extremely high’ levels, and the ticker added 20% more watchers. 
Via Stocktwits
Topics Death
News headline image
Here are the top movers in Tuesday's session. ↗
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
Dow Surges Over 600 Points; US Durable Goods Orders Fall in April ↗
 
Via Benzinga
Topics Stocks
News headline image
Rocket Pharma Reports Patient Death In Rare Disease Gene Therapy Trial, FDA Puts Clinical Hold ↗
Rocket Pharmaceuticals halted its Danon disease gene therapy trial after a patient death, with the FDA placing the study on clinical hold for review. 
Via Benzinga
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
Nasdaq Jumps Over 300 Points On EU Tariff Delay; AutoZone Posts Downbeat Earnings ↗
 
Via Benzinga
News headline image
Rocket Pharmaceuticals Stock Drops Pre-Market After FDA Pauses Gene Therapy Trial Over Patient Death: Retail Turns Bullish ↗
Rocket Pharmaceuticals said that it is working with the FDA to ensure safety of all study patients and resume the trial “as expeditiously as possible." 
Via Stocktwits
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharma's Gene Therapy Shows Promise in ACM Patients, Says Analyst ↗
Chardan's Geulah Livshits raises target price for RCKT to $46 and maintains Buy rating after promising data on gene therapy for heart disease. 
Via Benzinga
News headline image
Pentair To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
3 Stocks Insiders Are Buying Rapidly Amid Market Volatility ↗
Despite market volatility, these stocks are seeing strong buys by insiders. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Netflix, Ericsson, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Rocket Pharmaceuticals, Inc
Via Business Wire
News headline image
Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
From Rocket Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today